A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
Active, not recruiting · Phase 3 · NCT05063162
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
At a glance
- Research payments reported, 2025
- $3.3M
- U.S. investigators named
- 17
- Sites paid
- 27
- Planned or actual enrollment
- 113
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Rozanolixizumab (drug), Placebo (other)
- Dates
- Started 2022-02-02; completion 2027-07-01
- Results posted
- Not yet
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $3.3M in research payments for this study in 2025 (39 payments).
Products named: Rystiggo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jonathan L. Carter, M.D. Neurology · Scottsdale, AZ
- Cristina Valencia Sanchez, M.D. Neurology · Scottsdale, AZ
- Christopher B. Lock, MD Neurology · Stanford, CA
- Siok-hian Tay-kelley, NP Nurse Practitioners · Stanford, CA
- Jeffrey Bennett, MD Neurology · Aurora, CO
- Benjamin J. Osborne Neurology · Washington, DC
- Alfonso S. Lopez Chiriboga, M.D. Neurology · Jacksonville, FL
- Derrick S. Robertson, M.D. Neurology · Tampa, FL
- Jorge Kattah Neurology · Peoria, IL
- Sharon G. Lynch, M.D, Neurology · Kansas City, KS
- Michael Levy, M.D., PH.D. Neurology · Boston, MA
- Elias S. Sotirchos, M.D. Neurology · Baltimore, MD
- Eoin P. Flanagan, M.B.B.CH. Neurology · Rochester, MN
- Hesham A. Abboud, M.D. Neurology · Cleveland, OH
- Tania A. Reyna, MD Neurology · Tulsa, OK
- Kyle Blackburn, M.D. Neurology · Dallas, TX
- Larry V. Staker, MD Internal Medicine · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Massachusetts General Hospital, MA $737,329
- Neurology Center of North Orange Country A Medical Cord $625,976
- New York Medical College Office of Research $553,015
- University of Utah Hospital and Clinics, UT $397,955
- Osf Heart of Mary Medical Center, IL $391,817
- Johns Hopkins University $129,334
- Mayo Clinic Hospital, AZ $71,502
- University of Texas Health Science Center at San Antonio $62,555
- Georgetown University $61,959
- Mayo Clinic $51,641
- Regents of the University of Colorado $46,689
- UC Irvine Medical Center- Als & Neuromuscular Center $40,119
- The University of Texas Southwestern Medical Center $37,292
- Massachusetts General Hospital (mgh) - Neurology & Stroke Services $13,209
- Ut Health Science Center at San Antonio $12,699
- Mayo Clinic -Neurology $8,784
- University of Colorado Brain Imaging Center $8,740
- University of Utah School of Medicine - Neurology $8,536
- Uh Cleveland Medical Center, OH $6,090
- Stanford Neuroscience Health Center $4,835
- Mayo Clinic Jacksonville $1,670
- University of South Florida $1,320
- Ku Infectious Disease $668
- Saint Francis Medical Center, IL $614
- Ut Health Medical Arts & Research Center $580
- Medstar Georgetown University Hospital - Neurology $409
- Johns Hopkins Medicine Neurology & Neurosurgery - Transverse Myelitis Center $46
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.